Kathleen Moore, MD, discusses the benefit of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer.
Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, at Stephenson Cancer Center, discusses the benefit of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer.
The FORWARD-I/ GOG 3011 trial was a randomized, phase III study evaluating mirvetuximab soravtansine, a folate receptor alpha (FRα)—targeting antibody-drug conjugate. FRα is almost ubiquitously expressed—if not overexpressed—in high-grade serous ovarian cancer, says Moore.
Mirvetuximab soravtansine is an ideal target for drug delivery because it is not expressed on normal tissues. This allows for a concentration of conjugate on the ovarian cancer tumor cells and delivery of potent chemotherapy. In the trial, mirvetuximabsoravtansine was intended to show efficacy as compared with chemotherapy in patients with platinum-resistant ovarian cancer who had 1 to 3 prior lines of chemotherapy and overexpressed FRα on their tumor cells.